# Low-Dose Cannabis Extract Shows Promise for Alzheimer’s Disease > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/low-dose-thc-cbd-extract-alzheimers-clinical-trial/ > **Published:** 2026-03-18T23:20:24-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:43:29-04:00 > **Clinical Summary:** Explore the low-dose THC-CBD extract Alzheimer's clinical trial showing promise for cognitive improvement and safety in dementia patients. --- CED Clinical Relevance  #86High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 📋 Clinical Insight  |  CED Clinic Alzheimer’S DiseaseNeurologyThc-CbdDementia[Endocannabinoid System](https://cedclinic.com/endocannabinoid-system-fear-extinction/) Category Research Audience All Primary Topic PDF Analysis Why This Matters This represents the longest clinical trial to date evaluating cannabinoids in Alzheimer’s disease patients, providing crucial safety and efficacy data for a population with limited therapeutic options. The study’s 26-week duration and focus on low-dose THC-CBD extract addresses key clinical questions about sustained treatment in vulnerable elderly patients. Clinical Summary The phase 2 randomized controlled trial enrolled patients aged 60-80 with AD-associated dementia, administering daily low-dose THC-CBD extract (0.350mg THC, 0.245mg CBD) versus placebo for 26 weeks. Primary outcome showed statistically significant improvement in Mini-Mental State Exam scores in the cannabis group compared to placebo. The study found no significant differences in adverse events between groups, suggesting acceptable tolerability. The proposed mechanism involves compensating for [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) dysfunction commonly observed in AD, potentially modulating neuroinflammation, synaptic plasticity, and cellular clearance processes. However, secondary cognitive outcomes showed no significant differences, and the clinical meaningfulness of the MMSE improvement requires further validation. Dr. Caplan’s Take “While these results are encouraging, the modest effect size and single primary outcome warrant cautious optimism rather than clinical enthusiasm. I view this as important preliminary evidence that justifies larger, longer trials rather than definitive proof of therapeutic benefit.” Clinical Perspective 🧠 Patients and families should understand this represents early-stage research with promising but limited findings. The very low doses used suggest minimal intoxicating effects, but elderly patients with dementia require careful medical supervision for any cannabis intervention. Key questions for clinicians include optimal dosing protocols, patient selection criteria, and integration with existing AD medications like cholinesterase inhibitors. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Low-Dose%20Cannabis%20Extract%20Shows%20Promise%20for%20Alzheimer%27s%20Disease%20%40drcaplan&url=internal%3A//pdf-analysis/alzheimers-cannabis-trial)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=internal%3A//pdf-analysis/alzheimers-cannabis-trial)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Low-Dose%20Cannabis%20Extract%20Shows%20Promise%20for%20Alzheimer%27s%20Disease%20--%20via%20%40drcaplan.bsky.social%20internal%3A//pdf-analysis/alzheimers-cannabis-trial)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [internal://pdf-analysis/alzheimers-cannabis-trial](//pdf-analysis/alzheimers-cannabis-trial) Table of Contents - [Frequently Asked Questions](#Frequently_Asked_Questions)[Why should clinicians care about this topic?](#Why_should_clinicians_care_about_this_topic) - [Where can patients learn more?](#Where_can_patients_learn_more) - [How does this relate to the endocannabinoid system?](#How_does_this_relate_to_the_endocannabinoid_system) - [Related](#Related) ## Frequently Asked Questions ### Why should clinicians care about this topic? PDF analysis: Low-Dose Cannabis Extract Shows Promise for Alzheimer’s Disease ### Where can patients learn more? Visit cedclinic.com for evidence-based [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) resources, clinical consultations, and educational content from Dr. Caplan and the CED team. ### How does this relate to the endocannabinoid system? The endocannabinoid system is a fundamental regulatory network throughout the body. Understanding how it functions is essential for evidence-based [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice. {“@context”: “https://schema.org”, “@type”: “Article”, “headline”: “Low-Dose Cannabis Extract Shows Promise for Alzheimer’s Disease”, “url”: “internal://pdf-analysis/alzheimers-cannabis-trial”, “about”: “pdf analysis low dose cannabis extract”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Endocannabinoid System Research: Cannabis Mental Health Care](https://cedclinic.com/clinical-trial-cannabis-mental-health-research/) Explore how the endocannabinoid system impacts mental health and the therapeutic potential of [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). [Learn More](https://cedclinic.com/clinical-trial-cannabis-mental-health-research/) [CBD and CBG Promising Treatments for Fatty Liver Disease](https://cedclinic.com/cbd-cbg-fatty-liver-disease-study/) Discover recent findings on CBD and CBG as potential treatments for [fatty liver disease](https://cedclinic.com/cannabinoid-receptor-type-1-antagonist-obesity-steatohepatitis/) and their clinical implications. [Read Study](https://cedclinic.com/cbd-cbg-fatty-liver-disease-study/) [Endocannabinoid System Clinical Research: Pain Management Trial](https://cedclinic.com/full-spectrum-cannabis-extract-pain-trial/) Review [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) on the endocannabinoid system's role in pain management and cannabis-based therapies. [Explore Research](https://cedclinic.com/full-spectrum-cannabis-extract-pain-trial/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).